{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T18:37:19Z","timestamp":1695321439025},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,1]]},"DOI":"10.2146\/ajhp160886","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T11:35:16Z","timestamp":1511350516000},"page":"1959-1968","source":"Crossref","is-referenced-by-count":2,"title":["Recent advances in management of autosomal-dominant polycystic kidney disease"],"prefix":"10.1093","volume":"74","author":[{"given":"Jacob W.","family":"Potts","sequence":"first","affiliation":[{"name":"Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaker A.","family":"Mousa","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"issue":"suppl 4","key":"key\n\t\t\t\t2019041103415756500_b1-0741959","doi-asserted-by":"crossref","first-page":"iv15","DOI":"10.1093\/ndt\/gfu017","article-title":"Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival\u2014an analysis of data from the ERA-EDTA Registry","volume":"29","author":"Spithoven","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2019041103415756500_b2-0741959","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Polycystic kidney disease. http:\/\/kidney.niddk.nih.gov\/KUDiseases\/pubs\/polycystic\/ (accessed 2016 Oct 14)."},{"key":"key\n\t\t\t\t2019041103415756500_b3-0741959","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.2215\/CJN.01460210","article-title":"Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark","volume":"5","author":"Orskov","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041103415756500_b4-0741959","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2215\/CJN.00080605","article-title":"Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort","volume":"1","author":"Bae","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041103415756500_b5-0741959","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1053\/j.ackd.2010.01.003","article-title":"Extrarenal manifestations of autosomal dominant polycystic kidney disease","volume":"17","author":"Pirson","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"key\n\t\t\t\t2019041103415756500_b6-0741959","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1111\/j.1523-1755.2004.00921.x","article-title":"Pain patterns in patients with polycystic kidney disease","volume":"66","author":"Bajwa","year":"2004","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019041103415756500_b7-0741959","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/ckj\/sft031","article-title":"Hypertension in autosomal-dominant polycystic kidney disease (ADPKD)","volume":"6","author":"Sans-Atxer","year":"2013","journal-title":"Clin Kidney J"},{"key":"key\n\t\t\t\t2019041103415756500_b8-0741959","doi-asserted-by":"crossref","first-page":"468","DOI":"10.5527\/wjn.v4.i4.468","article-title":"Current management of autosomal dominant polycystic kidney disease","volume":"4","author":"Akoh","year":"2015","journal-title":"World J Nephrol"},{"key":"key\n\t\t\t\t2019041103415756500_b9-0741959","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4103\/0974-7796.91618","article-title":"Management of nephrolithiasis in autosomal dominant polycystic kidney disease\u2014a single center experience","volume":"4","author":"Baishya","year":"2012","journal-title":"Urol Ann"},{"key":"key\n\t\t\t\t2019041103415756500_b10-0741959","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/qjmed\/hct082","article-title":"The natural history of autosomal dominant polycystic kidney disease: 30-year experience from a single centre","volume":"106","author":"Thong","year":"2013","journal-title":"QJM"},{"key":"key\n\t\t\t\t2019041103415756500_b11-0741959","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12882-015-0114-5","article-title":"A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease","volume":"16","author":"Woon","year":"2015","journal-title":"BMC Nephrol"},{"key":"key\n\t\t\t\t2019041103415756500_b12-0741959","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nrneph.2015.128","article-title":"Vascular complications in autosomal dominant polycystic kidney disease","volume":"11","author":"Perrone","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"key\n\t\t\t\t2019041103415756500_b13-0741959","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1053\/j.ackd.2011.05.001","article-title":"The spectrum of polycystic kidney disease in children","volume":"18","author":"Dell","year":"2011","journal-title":"Adv Chronic Kidney Dis"},{"key":"key\n\t\t\t\t2019041103415756500_b14-0741959","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2015.59","article-title":"Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"88","author":"Chapman","year":"2015","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019041103415756500_b15-0741959","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1097\/01.ASN.0000028643.17901.42","article-title":"Genetics and pathogenesis of polycystic kidney disease","volume":"13","author":"Igarashi","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041103415756500_b16-0741959","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le Gall","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041103415756500_b17-0741959","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/ndt\/14.3.631","article-title":"Long-term follow-up of a family with autosomal dominant polycystic kidney disease type 3","volume":"14","author":"De Almeida","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2019041103415756500_b18-0741959","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/ki.2013.227","article-title":"Evidence of a third ADPKD locus is not supported by re-analysis of designated PKD3 families","volume":"85","author":"Paul","year":"2014","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019041103415756500_b19-0741959","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1097\/01.ASN.0000013300.11876.37","article-title":"The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease","volume":"13","author":"Rossetti","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041103415756500_b20-0741959","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/wdev.152","article-title":"Kidney: polycystic kidney disease","volume":"3","author":"Paul","year":"2014","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"key":"key\n\t\t\t\t2019041103415756500_b21-0741959","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1172\/JCI72272","article-title":"Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease","volume":"124","author":"Harris","year":"2014","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t2019041103415756500_b22-0741959","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1113\/jphysiol.2014.271346","article-title":"Polycystins and partners: proposed role in mechanosensitivity","volume":"592","author":"Retailleau","year":"2014","journal-title":"J Physiol"},{"key":"key\n\t\t\t\t2019041103415756500_b23-0741959","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041103415756500_b24-0741959","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified criteria for ultrasonographic diagnosis of ADPKD","volume":"20","author":"Pei","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041103415756500_b25-0741959","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.krcp.2016.04.004","article-title":"Genetic diagnosis of autosomal dominant polycystic kidney disease: linkage analysis versus direct mutation analysis","volume":"35","author":"Lee","year":"2016","journal-title":"Kidney Res Clin Pract"},{"key":"key\n\t\t\t\t2019041103415756500_b26-0741959","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/mgg3.82","article-title":"Diagnosis of autosomal dominant polycystic kidney disease using efficient PKD1 and PKD2 targeted next-generation sequencing","volume":"2","author":"Trujillano","year":"2014","journal-title":"Mol Genet Genomic Med"},{"key":"key\n\t\t\t\t2019041103415756500_b27-0741959","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ki.2015.71","article-title":"A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease","volume":"88","author":"Bhutani","year":"2015","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019041103415756500_b28-0741959","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3111\/13696998.2014.985381","article-title":"Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US","volume":"18","author":"Blanchette","year":"2015","journal-title":"J Med Econ"},{"key":"key\n\t\t\t\t2019041103415756500_b29-0741959","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103415756500_b30-0741959","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/1471-2369-14-186","article-title":"Renal replacement therapy in ADPKD patients: a 25-year survey based on the Catalan registry","volume":"14","author":"Martinez","year":"2013","journal-title":"BMC Nephrol"},{"key":"key\n\t\t\t\t2019041103415756500_b31-0741959","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/00007890-199611270-00006","article-title":"Preemptive cadaveric renal transplantation\u2014clinical outcome","volume":"62","author":"Roake","year":"1996","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t2019041103415756500_b32-0741959","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103415756500_b33-0741959","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","article-title":"Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells","volume":"66","author":"Belibi","year":"2004","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019041103415756500_b34-0741959","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t2019041103415756500_b35-0741959","unstructured":"Otsuka Pharmaceutical Co. Ltd. SAMSCA (tolvaptan) prescribing information. www.otsuka-us.com\/media\/static\/Samsca-PI.pdf (accessed 2016 Oct 14)."},{"key":"key\n\t\t\t\t2019041103415756500_b36-0741959","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2215\/CJN.06300615","article-title":"Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial","volume":"11","author":"Torres","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041103415756500_b37-0741959","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1369\/jhc.2008.950998","article-title":"Expression of somatostatin and somatostatin receptor subtypes 1\u20135 in human normal and diseased kidney","volume":"56","author":"Bhandari","year":"2008","journal-title":"J Histochem Cytochem"},{"key":"key\n\t\t\t\t2019041103415756500_b38-0741959","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1053\/j.ajkd.2013.10.011","article-title":"Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to halt disease progression in autosomal dominant polycystic kidney disease","volume":"63","author":"Meijer","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019041103415756500_b39-0741959","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041103415756500_b40-0741959","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial","volume":"137","author":"Van Keimpema","year":"2009","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t2019041103415756500_b41-0741959","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2215\/CJN.02650313","article-title":"Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study","volume":"9","author":"Braun","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041103415756500_b42-0741959","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103415756500_b43-0741959","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t2019041103415756500_b44-0741959","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2215\/CJN.08350813","article-title":"Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease","volume":"9","author":"Cadnapaphornchai","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041103415756500_b45-0741959","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.1007\/s11033-012-1611-2","article-title":"Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF\/Raf\/MAPK\/ERK signaling pathway","volume":"39","author":"Xu","year":"2012","journal-title":"Mol Biol Rep"},{"key":"key\n\t\t\t\t2019041103415756500_b46-0741959","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1681\/ASN.2012111089","article-title":"Reduced ciliary polycystin-2 in induced pluripotent stem cells from polycystic kidney disease patients with PKD1 mutations","volume":"24","author":"Freedman","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041103415756500_b47-0741959","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.3727\/096368914X684619","article-title":"Mesenchymal stromal cells improve renovascular function in polycystic kidney disease","volume":"24","author":"Franchi","year":"2015","journal-title":"Cell Transplant"},{"key":"key\n\t\t\t\t2019041103415756500_b48-0741959","doi-asserted-by":"crossref","first-page":"30013","DOI":"10.1038\/srep30013","article-title":"Identification of MMP1 as a novel risk factor for intracranial aneurysms in ADPKD using iPSC models","volume":"6","author":"Ameku","year":"2016","journal-title":"Sci Rep"},{"key":"key\n\t\t\t\t2019041103415756500_b49-0741959","doi-asserted-by":"crossref","first-page":"e0159526","DOI":"10.1371\/journal.pone.0159526","article-title":"Diffusive silicon nanopore membranes for hemodialysis applications","volume":"11","author":"Kim","year":"2016","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019041103415756500_b50-0741959","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.memsci.2008.09.039","article-title":"High-performance silicon nanopore hemofiltration membranes","volume":"326","author":"Fissell","year":"2009","journal-title":"J Memb Sci"},{"key":"key\n\t\t\t\t2019041103415756500_b51-0741959","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1007\/s10439-011-0256-y","article-title":"Hemocompatibility of silicon-based substrates for biomedical implant applications","volume":"39","author":"Muthusubramaniam","year":"2011","journal-title":"Ann Biomed Eng"},{"key":"key\n\t\t\t\t2019041103415756500_b52-0741959","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/MAT.0000000000000367","article-title":"First implantation of silicon nanopore membrane hemofilters","volume":"62","author":"Kensinger","year":"2016","journal-title":"ASAIO J"},{"key":"key\n\t\t\t\t2019041103415756500_b53-0741959","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1007\/s12274-014-0494-z","article-title":"Onchip detection of a single nucleotide polymorphism without polymerase amplification","volume":"7","author":"Han","year":"2014","journal-title":"Nano Res"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/74\/23\/1959\/28336855\/ajhp1959.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,6]],"date-time":"2019-10-06T16:07:35Z","timestamp":1570378055000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/74\/23\/1959\/5102723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,1]]},"references-count":53,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2017,12,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp160886","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,12,1]]},"published":{"date-parts":[[2017,12,1]]}}}